©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107919
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107919
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107919
Noninvasive prediction of Ki-67 expression in pancreatic cancer via contrast-enhanced ultrasound quantitative parameters: A diagnostic model study
Zi-Yi Yang, Wei-Na Wan, Lei Zhao, Si-Nong Li, Liang Sang, Department of Ultrasonography, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Zhe Liu, Department of Pancreatic-Biliary Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Co-first authors: Zi-Yi Yang and Wei-Na Wan.
Co-corresponding authors: Zhe Liu and Liang Sang.
Author contributions: Yang ZY responsible for the writing of the paper; Yang ZY, Liu Z and Sang L participated in the conception and design of the study and were involved in the acquisition, analysis of data; Wan WN and Zhao L did contrast examination for the patients; Li SN responsible for statistical calculations on the data.
Supported by the Liaoning Province Science and Technology Plan Joint Program, No. 2024JH2/102600310.
Institutional review board statement: This study was supported by the Medical Science Research Ethics Committee of the First Affiliated Hospital of China Medical University (No. AF-SOP-07-1.2-01).
Informed consent statement: Informed consent was obtained from all patients.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Liang Sang, MD, Doctor, Department of Ultrasonography, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. 20091213@cmu.edu.cn
Received: April 1, 2025
Revised: April 27, 2025
Accepted: May 21, 2025
Published online: June 15, 2025
Processing time: 73 Days and 5.3 Hours
Revised: April 27, 2025
Accepted: May 21, 2025
Published online: June 15, 2025
Processing time: 73 Days and 5.3 Hours
Core Tip
Core Tip: This study systematically integrates contrast-enhanced ultrasound quantitative parameters with pathological markers (Ki-67 index and tumor grade) in pancreatic cancer for the first time. By combining ultrasonography, tumor pathology, and statistical methods, it provides a noninvasive approach to assess tumor proliferation and aggressiveness. The findings may enable more precise treatment decisions (e.g., surgery, chemotherapy, or targeted therapy), potentially improving clinical outcomes.